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Infection, both bacterial and nonbacterial, may be associated with coagulation disorders,
resulting in disseminated intravascular coagulation and multiorgan failure. In the last few
decades a series of in vivo and in vitro studies has provided more insight into the pathogenetic
mechanisms and the role of cytokines in these processes. Because of the growing interest in
this field, the complexity of the subject, and the fact that many physicians must deal with a
variety of infections, current data are reviewed on the association between infectious diseases
and the coagulation system. Novel therapeutic intervention strategies that will probably be-
come available in the near future are mentioned, along with those of special interest for
infectious disorders for which only supportive care can be given.
Systemic infections may be complicated by activation of the
coagulation cascade, varying from subclinical activation, which
is indicated by a rise in laboratory markers for thrombin and
fibrin generation, to fulminant disseminated intravascular co-
agulation (DIC) with the formation of microvascular thrombi
in various organs [1]. Bleeding, thrombosis, or both may be the
presenting clinical features. DIC may contribute to multiorgan
failure (MOF) and is associated with a high mortality in both
bacterial and nonbacterial disease [2, 3].
Studies of gram-negative sepsis in humans and experimental
animals have shown that cytokines play a pivotal role in the
activation and regulation of the coagulation cascade, although
the interactions are complicated, and the effects are time-de-
pendent and transient [4]. Activation of the coagulation system
has also been documented for nonbacterial pathogens (i.e., vi-
ruses causing hemorrhagic fevers [HFs] [5, 6], protozoa [ma-
laria] [7, 8], and fungi [9]).
Since no specific effective treatment is yet available for DIC,
therapy focuses on treatment of the underlying disorder (e.g.,
antibiotics for bacterial infection). For many infectious dis-
eases, such as viral HF, causal therapy is not available, and
only supportive care can be provided. To improve therapy and
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supportive care, a better understanding of the pathogenesis of
bleeding and thrombotic complications is needed. Novel ther-
apeutic agents that intervene in the coagulation and cytokine
cascades will become available in the near future and may have
a positive clinical effect, especially for infections for which only
supportive care can be given.
Because of the growing interest in this field, the complexity
of the subject, and the fact that many physicians deal with a
variety of infections, we will review current data on the asso-
ciation between infectious diseases and the coagulation system.
Clinical Aspects of Hemostasis in Bacterial and Viral
Infections
Viral and bacterial infections may influence hemostasis and
can lead to thrombohemorrhagic complications or syndromes
such as DIC, hemolytic uremic syndrome (HUS), thrombotic
thrombocytopenic purpura (TTP), or vasculitis. Symptoms and
signs may be dominated by bleeding, thrombosis, or both.
DIC is an acquired disorder in which the hemostatic system
is activated, resulting in activation of platelets and the con-
version of fibrinogen to fibrin [3, 10]. This may lead to gen-
eralized microvascular thrombosis and MOF and to life-threat-
ening hemorrhage due to consumption of coagulation factors
and activation of the fibrinolytic system. DIC as a consumptive
coagulopathy, with consumption of both platelets and clotting
factors, must be distinguished from the nonconsumptive coag-
ulopathies, such as HUS and TTP, characterized by the con-
sumption of platelets but not clotting factors. HUS and TTP
are regarded as variants of a single syndrome characterized by
thrombocytopenia, hemolytic anemia, fever, renal abnormali-
ties, and neurologic disturbances. Endothelial injury is consid-
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Table 1. Viral infections hallmarked by hemorrhage or viral hemorrhagic fevers (HFs).
Virus Geographic distribution Source of infection
Dengue HF Southeast Asia, Caribbean, Central/South America, China Mosquito
Chikungunya Southeast Asia Mosquito
Ebola Zaire, Sudan Unknown
Marburg HF Zimbabwe, Kenya, Uganda Unknown
Lassa fever West Africa Rodent
Yellow fever South America, Africa Mosquito
Omsk HF Former Soviet Union Tick
Hantaan Central Europe, former Soviet Union, Korea, Japan, eastern China Rodent
ered the primary event, which, as shown in recent studies, may
lead to excessive release of extremely large polymers of von
Willebrand factor that cannot be processed to smaller forms
because of deficiency of von Willebrand factor–cleaving pro-
tease [11–14].
Vasculitis, which may be triggered by infection, is charac-
terized by local or more generalized vascular changes, resulting
from infarction secondary to occlusion by thrombi of the lumen
of small blood vessels in the upper part of the dermis. Vascular
occlusion may lead to ischemic tissue injury due to local vas-
cular occlusion or bleeding due to local tissue damage [15, 16].
None of these syndromes (DIC, MOF, HUS, TTP, or vas-
culitis) are specific for a certain pathogen, and their occurrence
depends on factors such as virulence of the pathogen, the pa-
tient’s prior condition, source and size of the inoculum, and
availability of antimicrobial treatment. For example, these co-
agulopathic syndromes are encountered more frequently in
gram-negative infection than in gram-positive and other non-
bacterial infections. Vasculitis (i.e., cytomegalovirus [CMV]
vasculitis) occurs in human immunodeficiency virus (HIV)–
immunocompromised persons but is rare in persons not im-
munodepressed, underlining the role of the host’s status. There
is a relation between the size of the inoculum and the occurrence
of the sepsis syndrome, as has been shown in an experimental
gram-negative sepsis model in baboons [17].
In some cases of MOF, bleeding and (microvascular) throm-
bosis may be coexisting features, making it impossible to de-
termine the principal defect (thrombosis or bleeding). Taking
these considerations into account, the classification of clinical
entities according to bleeding or thrombosis will be the basis
for discussion, although the complexity and overlap in clinical
presentation must be kept in mind.
Hemorrhage. Hemorrhage may occur as a single clinical
phenomenon or may be part of a more complex derangement
of the coagulation cascade due to DIC or septic vasculitis, as
in gram-negative bacterial sepsis (i.e., meningococcemia [1, 3,
16]). Severity may vary from local defects in hemostasis with
oozing from arterial or venous puncture sites to more general
complications, such as petechiae, purpura, ecchymosis, gut
bleeding, hemoptysis, or even MOF due to adrenal bleeding
(as in Waterhouse-Friderichsen syndrome). The clinical signs
are not pathogen-specific and in general depend on the severity
of infection. In specific infections, such as viral HF, bleeding
complications are prominent [18–20]. Among the viral HFs,
Dengue [18–20], Marburg [21, 22], and Ebola [23, 24] are the
most important. Dengue is the most prevalent (table 1).
Bacterial and viral infections may result in a vasculitis-like
syndrome with either bleeding manifestations or ischemic injury
[15, 16, 25]. Vasculitis is well documented in CMV infection
[26, 27], occurring predominantly in the vasculature of the gas-
trointestinal tract, where it causes colitis [28, 29]; the central
nervous system, where it causes cerebral infarction [30, 31]; and
the skin, where it results in petechiae, purpura papules, localized
ulcers, or a diffuse maculopapular eruption [32].
HIV infection may be accompanied by vasculitis syndromes,
such as polyarteritis nodosa, Henoch-Schönlein purpura, and
leukocytoclastic vasculitis [33–36]. Hepatitis B and C infection
may cause polyarteritis-like vasculitis [37–39]. Parvovirus B19
has been suggested to be associated with vasculitis-like syn-
dromes, including Kawasaki disease, polyarteritis nodosa, and
Wegener’s granulomatosis [40–42].
Leptospirosis, especially Weil’s syndrome, may present with
hemoptysis, epistaxis, intestinal bleeding, adrenal bleeding, he-
maturia, and even subarachnoid hemorrhage [43]. The path-
ogenesis may be either primary activation of coagulation or
diffuse vasculitis, resulting in bleeding or ischemia of the vas-
cularized tissue. TTP, with bleeding as the presenting symptom,
may also occur in the course of Weil’s syndrome [44]. In other
viral and bacterial infections associated with TTP or HUS,
bleeding also is often the prominent and presenting symptom
[45–47].
Thrombosis and hemorrhage: DIC. Viral and bacterial in-
fections may theoretically result in local thromboembolic dis-
ease, that is, deep venous thrombosis or pulmonary embolism.
In a thromboembolic prevention study of low-dose subcuta-
neous standard heparin for hospitalized patients with infectious
diseases, morbidity due to thromboembolic disease was signif-
icantly reduced in the heparin group, compared with the group
receiving no prophylaxis. There was, however, no beneficial
effect of prophylaxis on mortality due to thromboembolic com-
plications [48]. In chronic viral diseases, such as CMV or HIV
infection, the risk of thromboembolic complications is relatively
low [49, 50].
MOF is a clinical entity characterized by generalized micro-
vascular thrombosis that may develop as part of the DIC syn-
drome, especially in bacterial gram-negative sepsis but also in
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Figure 1. Model of hypothetical coagulation cascade. Products of coagulation activation are shown in squares: IXp, factor IX activation
peptide; Xp, factor X activation peptide; F1 1 2, prothrombin fragment ; FPA, fibrinopeptide A; D-dimer, fibrin split product; TAT, thrombin-1 1 2
antithrombin complex. Natural inhibitors shown: TFPI, tissue factor pathway inhibitor; AT, antithrombin; PCa, activated protein C (which cleaves
activated factors V and VIII). Coagulation proteins are given in roman numerals: PK, prekallikrein; HK, high–molecular weight kininogen; TAFI,
recently identified “thrombin activatable fibrinolytic inhibitor.”
severe viral infections. Viral HF (table 1) is complicated by
DIC in the most severe cases [18–24]. DIC is not frequently
encountered in other viral infections [51, 52] but has been found
in cases of rotavirus [53, 54], varicella, rubella, rubeola, and
influenza infections [55–61].
TTP and HUS, triggered by a viral or bacterial infection
[45–47], frequently lead to bleeding symptoms, as has been
discussed, but platelet and fibrin thrombi may also be generated
in various organs, leading to prominent symptoms with organ
dysfunction. The variety and complexity of the clinical presen-
tation of the coagulopathy syndromes confront the clinician
with the difficult questions of whether, when, and how to pro-
vide optimal supportive care to combat the coagulation dis-
orders in addition to giving antimicrobial therapy. In making
this decision, he or she will probably be guided by the clinically
most pronounced presenting symptom.
Principles of Hemostasis, Coagulation, and Fibrinolysis:
General Aspects
The hemostatic mechanism consists of primary hemostasis,
coagulation, and fibrinolysis (figure 1). Primary hemostasis is
maintained by the adhesion and aggregation of platelets to form
a hemostatic plug that is stabilized by fibrin strands [62, 63].
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Coagulation, the second hemostatic defense mechanism, is gen-
erated by a series of linked coagulation protease-zymogen re-
actions, ultimately resulting in the formation of fibrin. In the
current concept of coagulation, thrombin generation is induced
by the assembly of tissue factor (TF) VIIa complex, the so-
called extrinsic route of coagulation.
Coagulation is counteracted by different inhibitory mecha-
nisms. A first mechanism is made up of the circulating inhibitors
of blood coagulation, that is, antithrombin, proteins C and S,
and TF pathway inhibitor (TFPI). A second inhibitory mech-
anism consists of the endothelium-bound modulators heparin
sulfate and thrombomodulin, which facilitate the inhibitory ac-
tivity of antithrombin and protein C, respectively. The third
mechanism, the fibrinolytic system, is activated by tissue plas-
minogen activator (tPA) and urokinase after their synthesis and
release from the endothelial cell system. These activators initiate
the conversion of plasminogen to plasmin, which hydrolyzes
polymerized fibrin strands into soluble fibrin degradation prod-
ucts. Infection may lead to an imbalance between platelet func-
tion and the regulatory mechanisms of the coagulation cascade
and fibrinolysis, resulting in bleeding, thrombosis, or both.
Pathophysiologic Mechanisms of Hemostasis in Bacterial
and Viral Infection
On the basis of data from experimental studies that have
revealed the complexity of the interactions among infectious
pathogens, cytokines, effector cells, and the coagulation system,
we will discuss current insights into the pathogenesis of ab-
normal hemostasis in infectious diseases. Cytokines are thought
to play an essential role in activation of the coagulation system
during viral and bacterial infections [64, 65].
Coagulation Activation
TF pathway. The TF pathway (extrinsic route) is the main
route for activation of the coagulation cascade in sepsis. En-
dotoxins, lipopolysaccharide constituents of the outer
membrane of gram-negative microorganisms, play a pivotal
role in the development of the gram-negative sepsis syndrome
[66]. Levels of circulating endotoxin are prognostic markers for
the clinical outcome of the septic syndrome [67, 68]. Injection
of endotoxin or tumor necrosis factor (TNF)–a into healthy
volunteers results in activation of the coagulation system via
activation of the TF pathway [64, 69–71]. TNF-a injected into
volunteers initiates the release of interleukin (IL)–6 and IL-8,
which is followed by an increase in the levels of circulating
markers of thrombin and fibrin generation (prothrombin frag-
ments [F1 1 F2], thrombin-antithrombin complexes [TAT], fi-
brinopeptide A) [17, 64, 72]. This activation is preceded by a
primary but transient activation of fibrinolysis; in contrast, af-
ter activation of the coagulation cascade, activation of fibri-
nolysis is secondary [52]. The net effect of an injection of en-
dotoxin or TNF-a is a procoagulant state. In this experimental
model, coagulation and fibrinolysis seem to be activated in-
dependently, which may lead to an imbalance between acti-
vation of coagulation and regulation (activation/inhibition) of
fibrinolysis [73]. The same imbalance has been observed in ba-
boons after injection of IL-1 [74]. Administration of IL-6 into
patients with renal cell carcinoma also results in activation of
coagulation, as reflected by a rise in the concentration of F1 1
F2 and TAT complexes, but here fibrinolysis is not affected
[75].
TNF-a induces the expression of TF on monocytes [76] and
endothelial cells [77–79]. In chimpanzees and baboons, anti-
bodies directed against TF or factor VIIa or treatment with
TFPI prevents activation of the common pathway [71, 80–84],
whereas antibodies directed against factor XII do not prevent
activation [85, 86], emphasizing the role of the TF pathway.
IL-10 can inhibit the coagulant response during systemic in-
fection by influencing the expression of TF on monocytes [87,
88].
As mentioned above, TNF is not an essential factor in the
mediation of activation of coagulation in sepsis. This has be-
come evident from studies of volunteers treated with anti-TNF
in which endotoxin-induced activation of coagulation did not
change [89, 90]. Surprisingly, administration of IL-1ra, a major
natural inhibitor of IL-1, results in inhibition of both the co-
agulation cascade and fibrinolysis in baboons with lethal bac-
teremia and patients with the sepsis syndrome [74, 91]. Treat-
ment of patients with IL1-ra is associated with decreases in the
concentrations of TAT and plasmin-a2 antiplasmin (PAP) com-
plexes and tPA and plasminogen activator inhibitor (PAI)–1
[91]. Treating chimpanzees with anti–IL-6 after the adminis-
tration of low-dose endotoxin prevents activation of the co-
agulation cascade but does not affect fibrinolysis [92]. In con-
clusion, activation of the TF pathway after endotoxin release
is largely, although not exclusively, mediated and regulated by
cytokines.
Contact activation. Although the factor XII pathway does
not seem to play an essential role in activation of the coagu-
lation cascade in experimental sepsis in baboons [85, 86], block-
ing of the contact activation system by the administration of
monoclonal antibodies against factor XIIa could prevent lethal
hypotension. This effect is most probably mediated by the gen-
eration of kinins, such as bradykinin [85]. Moreover, the contact
system seems to play an independent role in the activation of
the fibrinolytic system [93]. However, the importance of this
route in sepsis has not yet been completely clarified (table 2).
Endothelial Cell and TF Expression
The role of endothelial cells seems to be crucial in the de-
velopment of shock and activation of coagulation [94–96]. En-
dothelial cell injury is a common feature of viral infection and
can alter hemostasis in a direct or indirect manner. The en-
180 van Gorp et al. JID 1999;180 (July)
Table 2. Viruses infecting endothelial cells.
Viruses
Dengue virus Herpes simplex virus
Ebola virus Poliovirus
Marburg virus Adenovirus
Hantaan virus Parainfluenza virus
Cytomegalovirus Echovirus
Measles Human immunodeficiency virus
Human T cell leukemia virus type 1 Mumps
Figure 2. Endothelial cell in infection. During infection, endothelial cell may change to procoagulant state by expressing tissue factor on
membrane. Tissue factor is main inducer of extrinsic pathway of blood coagulation. Increased endothelial permeability resulting in plasma leakage
may be the consequence of local or more generalized inflammatory response, with increased leukocyte adherence to endothelial cell. This mechanism
is triggered by up-regulation of endothelial cell adhesion molecules (i.e., intercellular adhesion molecule 1, vascular cell adhesion molecule 1, E-
selectin, P-selectin).
dothelial cell can be directly infected by different viruses [97–99],
for example, herpes simplex, adenovirus, parainfluenzavirus,
poliovirus, echovirus, measles, mumps [100], CMV [101], hu-
man T cell leukemia virus type 1 [102], and HIV [103]. The
ability to infect endothelial cells has also been demonstrated in
HFs caused by Dengue, Marburg, Ebola, Hantaan, and Lassa
viruses [104]. Such infections may result in a procoagulant state,
mainly by inducing TF expression on the endothelial surface
[105–107], probably mediated by cytokines such as IL-1
[105–112], TNF-a, and IL-6 [113–115].
An additional cause of enhanced coagulability may be pro-
thrombinase complex assembly on the CMV surface [116]. This
observation suggests that the CMV surface contains the nec-
essary procoagulant phospholipids for assembly of the coag-
ulation enzyme complex leading to thrombin generation. A
similar observation has been made for HIV [117]. However not
all viral infections affecting endothelial cells result in activation
of coagulation, which may indicate that activation of endo-
thelium is one factor in a multifactorial process (figure 2).
Fibrinolysis
General aspects. The process of fibrinolysis involves the
enzymatic cascade, which helps to break down cross-linked fi-
brin molecules. Fibrinolysis may be activated primarily—and
thus independently of activation of the coagulation cascade—or
secondarily in response to fibrin formation. If fibrinolysis is not
balanced in time and scope, either bleeding or thrombosis may
ensue. After the injection of TNF into healthy volunteers, ac-
tivation of the coagulation cascade is preceded by a transient
activation of fibrinolysis, which is reflected by increased cir-
culating levels of tPA and urokinase plasminogen activator,
followed by an increase in PAI-I, suppressing fibrinolysis [64,
72, 118, 119]. Coagulation activation triggers a secondary ac-
tivation of fibrinolysis [52], which is rapidly shut off by the
release of relatively large amounts of PAI-I, such that the net
effect of the injection of a bolus of endotoxin is a procoagulant
state.
Infusion of IL-1a into baboons also elicits an early and tran-
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sient activation of fibrinolysis [74] followed by the production
of PAI-1, leading to a balance. Fibrinolytic activation is fol-
lowed by activation of coagulation, thus showing the same
imbalance between coagulation and fibrinolysis observed after
the administration of TNF-a. This procoagulant imbalance is
also present in DIC, where the net effect will be a tendency
toward diffuse bleeding and microvascular thrombosis.
Treatment with anti-TNF in the human and chimpanzee sep-
sis models inhibits the fibrinolytic system, as reflected by the
absence of a rise in tPA, PAI-1, and PAP complexes [89, 90,
120], whereas coagulation is not affected, showing that TNF
plays an important role in regulation of the fibrinolytic re-
sponse. Administration of IL-1ra into baboons with lethal bac-
teremia or patients with sepsis inhibits both coagulation and
fibrinolysis [74, 91], as indicated by decreased concentrations
of TAT and PAP complexes and tPA and PAI-1 [91]. Treating
chimpanzees with anti–IL-6 after the administration of low-
dose endotoxin prevents activation of the coagulation cascade
and does not affect fibrinolysis [91].
Protein C/S system. During sepsis, the protein C/S system
is down-regulated [121]. After the release of TNF-a, throm-
bomodulin is also down-regulated, resulting in a further de-
crease in protein C activity, thereby enhancing the procoagulant
state. Some viruses can induce specific changes in the coagu-
lation inhibitory system. During the course of HIV infection,
the protein C/S system may be impaired as a result of an ac-
quired protein S deficiency, the pathogenesis of which is not
yet clarified [122–125]. In children, protein S deficiency seems
to correlate with the duration of HIV infection [122], but such
a relationship has not been found in adults [123]. Increased
plasma concentrations of the C4b-binding protein, an acute-
phase protein that binds protein S, may result in decreased levels
of free protein S. Antiphospholipid antibodies, which may be
present in persons infected with HIV, might interfere with the
protein C–protein S complex and diminish its activity [123,
126–129]. In patients with Dengue HF, we also found decreased
levels of both protein C and protein S activity (current authors,
unpublished data). As in Dengue infection, HIV can affect the
endothelial cell; hypothetically, this could lead to decreased pro-
duction of protein S.
Thrombocytopenia
Thrombocytopenia is seen in the course of many viral in-
fections but is only occasionally serious enough to lead to he-
mostatic impairment and bleeding complications [130]. It is
assumed that thrombocytopenia is mainly immune mediated
[131]. The mechanism is decreased thrombopoiesis [132, 133],
increased platelet consumption [134], or a combination of both.
Direct interaction of the virus with platelets [5, 135, 136] may
lead to thrombocytopenia or thrombocytopathy. Endothelial
injury by the virus [137] may lead to increased adherence and
consumption of platelets [138].
Viral infections that have been associated with thrombocy-
topenia are mumps [139, 140], rubella [141–143], rubeola [144],
varicella [145–147], disseminated herpes simplex [148], CMV
infection [149, 150], infectious mononucleosis [151–155], Han-
taan virus infection [156, 157], Dengue HF [5, 135, 158], Cri-
mean-Congo HF [159], and Marburg HF [160]. Dengue fever
is associated with thrombocytopenia even in mild and uncom-
plicated cases [5]; therefore, thrombocytopenia cannot be the
only explanation for the occurrence of bleeding.
Soluble Adhesion Molecules
The change of the endothelial cell from a resting to a pro-
coagulant state may be associated with expression of endothe-
lial surface adhesion molecules [112, 161, 162]. These molecules,
that is, the intercellular adhesion molecule, the vascular cell
adhesion molecule, E-selectin, and the von Willebrand factor,
play an essential role in the binding of leukocytes, resulting in
a local inflammatory response, endothelial cell damage, and
subsequent plasma leakage and shock [163–166]. Vasculitis also
occurs and has been documented in association with such vi-
ruses as CMV and HIV [26, 167, 168]. The finding of increased
plasma concentrations of these endothelial surface adhesion
molecules is thought to reflect the level of activation and per-
haps damage of the endothelial cell. Measuring circulating
endothelial cells by immunofluorescence or immunomagnetic
separation may provide additional information about the ac-
tivation of vascular endothelium [169–171].
Conclusions
Infectious diseases are often accompanied by activation of
coagulation. Although direct interactions between the infec-
tious agent and the coagulation system occur, cytokines are
believed to be important mediators in this process. During sys-
temic gram-negative and gram-positive bacterial infections, ac-
tivation of coagulation is mediated via the extrinsic TF path-
way. Experimental studies suggest that, as a rule, coagulation
and fibrinolysis occur independently of one another, and the
overall result is usually a procoagulant tendency. The latter may
result in DIC with microvascular thrombosis and organ failure.
Bleeding may result from consumption of platelets and clotting
proteins in traumatized tissues.
Although this scenario has been derived largely from studies
with purified endotoxin or gram-negative bacteria, we expect
similar alterations to occur in gram-positive and in specific viral
infections, because some of the key intermediate cytokines
(TNF, IL-1, IL-6) are involved. It should be noted, however,
that the mechanisms by which viruses presumably induce co-
agulation in vivo are still speculative, since only in vitro data
are available. The critical cellular elements involved in these
reactions may not be the same for bacterial and viral infections,
but we speculate that the vascular endothelium is a main target.
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Endothelial cells may turn into a procoagulant state either by
stimulation of cytokines in concert with circulating blood cells,
such as lymphocytes or platelets, or by direct infection (viruses)
of endothelial cells.
Bleeding in infectious disease is most likely a multifactorial
process resulting from a combination of thrombocytopenia,
consumption of clotting factors, (local) hyperfibrinolysis, and
vascular damage or leakage. In addition, immunologically me-
diated vasculitis may contribute to bleeding in specific
infections.
The clinical consequences of chronic viral infections (e.g.,
CMV and HIV) for the development of thrombotic compli-
cations, vasculitis, and atherosclerosis are of great interest. One
could hypothesize that since CMV infection may lead to trans-
formation of the endothelial cell to a procoagulant state but
may also induce vasculitis and atherosclerosis [172], there could
well be a common pathway in the pathophysiologic mechanism
of these physiologic and anatomic entities. The role of other
pathogens, such as Chlamydia pneumoniae that have the po-
tency to affect the endothelium and contribute to the patho-
genesis of atherosclerosis is of interest [173–175].
Knowledge of the underlying mechanisms leading to throm-
bosis or bleeding is fundamental for the development of ther-
apeutic strategies. In gram-negative infections, insight into the
important roles of endotoxin and specific cytokines has already
led to clinical therapeutic trials with selective inhibitors of the
TF pathway (monoclonal antibodies, Fab fragments, modified
factor VIIa, nematode anticoagulant protein, TFPI) [176, 177].
Studies with anti-TF antibodies and TFPI in primates have
shown that, in addition to inhibition of coagulation activity,
these agents may have significant anti-inflammatory properties
and may markedly reduce mortality in otherwise lethal infec-
tions [178, 179].
Given the potential role that endothelial TF may play in
some of the thrombohemorrhagic complications of viral dis-
ease, we expect that therapeutic intervention at the TF level or
aimed at one of the critical cytokines that mediate its cellular
expression may potentially favorably alter the clinical course
of these infections. Many issues remain to be answered, and
thus there is an urgent need for more clinical and experimental
studies, particularly with respect to the relationship between
viral infections and the mechanisms leading to bleeding/DIC.
Needless to say, treatment of the causal infectious agent remains
the cornerstone of therapy.
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ner’s granulomatosis and parvovirus B19 infection Arthritis Rheum
1994;37:1707–8.
42. Yoto Y, Kudoh T, Haseyama K, Suzuki N, Chiba S, Matsunaga Y. Human
parvovirus B19 infection in Kawasaki disease. Lancet 1994;344:58–9.
43. Lecour H, Miranda M, Magro C, et al. Human leptospirosis—a review of
50 cases. Infection 1989;17:8–12.
44. Laing RW, Teh C, Toh CH. Thrombotic thrombocytopenic purpura (TTP)
complicating leptospirosis: a previously undescribed association. J Clin
Pathol 1990;43:961–2.
45. Badesha PS, Saklayen MG. Hemolytic uremic syndrome as a presenting
form of HIV infection. Nephron 1996;72:472–5.
46. Chu QD, Medeiros LJ, Fisher AE, Chaquette RF, Crowley JP. Thrombotic
thrombocytopenic purpura and HIV infection. South Med J 1995;88:
82–6.
47. Qadri SM, Kayali S. Enterohemorrhagic Escherichia coli. A dangerous food-
borne pathogen. Postgrad Med 1998;103:179–80.
48. Gardlund B. Randomised controlled trial of low dose heparin for prevention
of fatal pulmonary embolism in patients with infectious diseases. The
heparin prophylaxis study group. Lancet 1996;347:1357–61.
49. Laing RBS, Brettle RP, Leen CLS. Venous thrombosis in HIV infection.
Int J STD AIDS 1996;7:82–5.
50. Jenkins RE, Peters BS, Pinchin AJ. Thromboembolic disease in AIDS is
associated with cytomegalovirus disease. AIDS 1991;5:1540–2.
51. Marder VJ. Consumptive thrombohemorrhagic disorders. In: Williams WJ,
Beutler E, Erslev AJ, Lichtman MA, eds. Hematology. 3rd ed. New
York: McGraw-Hill, 1983:1433–61.
52. Marder VJ, Feinstein DI, Francis CW, Colman RW. Consumptive throm-
bohemorrhagic disorders. In: Colman RW, Hirsh J, Marder VJ, Salzman
EW, eds. Hemostasis and thrombosis: basic principles and clinical prac-
tice. 3rd ed. Philadelphia: JB Lippincott, 1994:1023–63.
53. Limbos MA, Lieberman JM. Disseminated intravascular coagulation as-
sociated with rotavirus gastroenteritis: report of two cases. Clin Infect
Dis 1996;22:834–6.
54. WHO scientific working group. Rotavirus and other viral diarrheas. Bull
World Health Organ 1980;58:183–98.
55. McKay DG, Margaretten W. Disseminated intravascular coagulation in
virus diseases. Arch Intern Med 1967;120:129–52.
56. Linder M, Müller-Berghaus G, Lasch HG, Gagel. Virus infection and blood
coagulation. Thromb Diath Haemorrh 1970;23:1–11.
57. Talley NA, Assumpcao CAR. Disseminated intravascular clotting compli-
cating viral pneumonia due to influenza. Med J Aust 1971;2:763–6.
58. Davison AM, Thomson D, Robson JS. Intravascular coagulation compli-
cating Influenza A virus infection. Br Med J 1973;1:654–5.
59. Whitaker AN, Bunce I, Graeme ER. Disseminated intravascular coagula-
tion and acute renal failure in Influenza A2 infection. Med J Aust 1974;2:
196–201.
60. Settle H, Glueck HI. Disseminated intravascular coagulation associatedwith
influenza. Ohio State Med J 1975;71:541–3.
61. Anderson DR, Schwartz J, Hunter NJ, Cottrill C, Bisaccia E, Klainer AS.
Varicella hepatitis: a fatal case in a previously healthy, immunocompetent
adult. Arch Intern Med 1994;154:2101–5.
62. Davie EW, Fujikawa K, Kisiel W. The coagulation cascade: initiation, main-
tenance, and regulation. Biochemistry 1991;30:10363–70.
63. Van Gorp ECM, ten Cate H. Coagulation monitoring. In: Webb AR, Shapiro
MJ, Singer M, Suter PM, eds. Oxford textbook of critical care medicine.
Oxford, UK: Oxford University Press, 1999:1170–3.
64. Van Deventer SJH, Buller HR, ten Cate JW, Aarden LA, Hack CE, Sturk
A. Experimental endotoxinaemia in humans: analysis of cytokine release
and coagulation, fibrinolytic, and complement pathways. Blood 1990;
76:2520–6.
65. Michie HR, Manogue KR, Spriggs DR, et al. Detection of circulating tumor
necrosis factor after endotoxin administration. N Engl J Med 1988;318:
1481–6.
66. Morrison DC, Ryan JC. Endotoxin and disease mechanisms. Annu Rev
Med 1987;38:417–32.
67. Brandtzaeg P, Kieruif P, Gaustad P, et al. Plasma endotoxin as a predictor
of multiple organ failure and death in systemic meningococcal disease.
J Infect Dis 1989;159:195–204.
68. Van Deventer SJH, Büller HR, ten Cate JW, Sturk A, Pauw W. Endotoxi-
naemia: an early predictor of septicemia in febrile patients. Lancet
1988;1:605–9.
69. Bauer KA, ten Cate H, Barzegar S, Spriggs DR, Sherman ML, Rosenberg
RD. Tumor necrosis factor infusions have a procoagulant effect on the
hemostatic mechanism of humans. Blood 1989;74:165–72.
70. van der Poll T, Buller HR, ten Cate H, et al. Activation of coagulation
after administration of tumor necrosis factor to normal subjects. N Engl
J Med 1990;322:1622–7.
71. Levi M, ten Cate H, Bauer KA, Buller HR, ten Cate JW, Rosenberg RD.
Dose dependent endotoxin induced cytokine release and coagulation
activation in chimpanzees. Thromb Haemost 1991;65:793.
72. Suffredini AF, Harpel PC, Parillo JE. Promotion and subsequent inhibition
184 van Gorp et al. JID 1999;180 (July)
of plasminogen activator after administration of intravenous endotoxin
to normal subjects. N Engl J Med 1989;320:1165–72.
73. van der Poll T, Levi M, van Deventer SJH. TNF and the dysbalance between
coagulant and anticoagulant mechanisms in septicemia. Update. Inten-
sive Care Emerg Med 1990;14:269–73.
74. Jansen PM, Boermeester MA, Fischer E, et al. Contribution of interleukin-
1 to activation of coagulation and fibrinolysis, to neutrophil degranu-
lation and the release of sPLA2 in sepsis. Studies in non-human primates
following interleukin 1a administration and during lethal bacteremia.
Blood 1995;86:1027–34.
75. Stouthard JML, Levi M, Hack CE, et al. Interleukin-6 stimulates coagu-
lation, not fibrinolysis, in humans. Thromb Haemost 1996;76:738–42.
76. Conkling PR, Greenberg CS, Weinberg JB. Tumor necrosis factor induces
tissue factor-like activity in human leukemia cell line U937 and peripheral
blood monocytes. Blood 1988;72:128–33.
77. Conway EM, Bach R, Rosenberg RD, Konigsberg WH. Tumor necrosis
factor enhances expression of tissue factor mRNA in endothelial cells.
Thromb Res 1989;53:231–41.
78. Bevilacqua MP, Pober JS, Majeau GR, Fiers W, Cotran RS, Gimbrone MA.
Recombinant tumor necrosis factor produces pro-coagulant activity in
cultured human vascular endothelium. Proc Natl Acad Sci USA 1986;
83:4533–7.
79. Osterud B, Flaegstad T. Increased tissue thromboplastin activity in mono-
cytes of patients with meningococcal infections related to unfavourable
prognosis. Thromb Haemost 1983;49:5–7.
80. Levi M, ten Cate H, Bauer KA, et al. Inhibition of endotoxin induced
activation of coagulation and fibrinolysis by pentoxifylline or by a mono-
clonal anti-tissue factor antibody in chimpanzees. J Clin Invest 1994;93:
114–20.
81. Taylor FB Jr, Chang A, Ruf W, et al. Lethal E. coli septic shock is prevented
by blocking tissue factor with monoclonal antibody. Circ Shock 1991;
33:127–34.
82. Creasy AA, Chang ACK, Feigen L, Wün TC, Taylor FB Jr, Hinshaw LB.
Tissue factor pathway inhibitor reduces mortality from Escherichia coli
septic shock. J Clin Invest 1993;91:2850–60.
83. Biemond BJ, ten Cate H, Levi M, et al. Complete inhibition of endotoxin-
induced coagulation activation in chimpanzees with a monoclonal Fab
fragment against factor VII/VIIa. Thromb Haemost 1995;73:223–30.
84. Biemond BJ, ten Cate H, Levi M, et al. Complete inhibition of endotoxin
induced coagulation activation in chimpanzees with a monoclonal an-
tibody to factor VII/VIIa. Circulation 1992;86:679.
85. Pixley RA, de la Cadena R, Page JD, et al. The contact system contributes
to hypotension but not to disseminated intravascular coagulation in
lethal bacteremia. J Clin Invest 1993;91:61–8.
86. Pixley RA, de la Cadena, Page JD, et al. Activation of the contact system
in lethal hypotensive bacteremia in a baboon model. Am J Pathol
1992;140:897–906.
87. Pajkrt D, van der Poll T, Levi M, et al. Interleukin 10 inhibits activation
of coagulation and fibrinolysis during human endotoxemia. Blood
1997;89:2701–5.
88. Pradier O, Gérard C, Delvaux A, et al. Interleukin-10 inhibits the induction
of monocyte procoagulant activity by bacterial lipopolysaccharide. Eur
J Immunol 1993;23:2700–4.
89. van der Poll T, Levi M, van Deventer SJH, et al. Differential effects of anti-
tumor necrosis factor monoclonal antibodies on systemic inflammatory
responses in experimental endotoxemia in chimpanzees. Blood 1994;83:
446–51.
90. van der Poll T, Coyle SM, Levi M, et al. Effect of recombinant dimeric
tumor necrosis factor receptor on inflammatory responses to intravenous
endotoxin in normal humans. Blood 1997;89:3727–34.
91. Boermeester MA, van Leeuwen PAM, Coyle SM, et al. Interleukin-1 re-
ceptor blockade in patients with sepsis syndrome: evidence that inter-
leukin-1 contributes to the release of interleukin-6, elastase and phos-
pholipase A2, and to the activation of the complement, coagulation and
fibrinolytic systems. Arch Surg 1995;130:739–48.
92. van der Poll T, Levi M, Hack CE, et al. Elimination of interleukin 6 at-
tenuates coagulation activation in experimental endotoxemia in chim-
panzees. J Exp Med 1994;179:1253–9.
93. Levi M, Hack CE, de Boer JP, Brandjes DPM, Büller HR, ten Cate JW.
Reduction of contact activation related fibrinolytic activity in factor XII
deficient patients: further evidence for the role of the contact system in
fibrinolysis in vivo. J Clin Invest 1991;88:1155–60.
94. Cotran RS. The endothelium and inflammation: new insights. Monogr
Pathol 1982;23:18–37.
95. Stemerman MB, Colton C, Morell E. Perturbations of the endothelium.
Prog Hemost Thromb 1984;7:289–324.
96. Kaiser L, Sparks HV Jr. Endothelial cells: not just a cellophane wrapper.
Arch Intern Med 1987;147:569–73.
97. Friedman H, Macarak E, MacGregor R, Wolfe J, Kefalides N. Virus in-
fection in endothelial cells. J Infect Dis 1981;143:266–73.
98. Friedman H, Wolfe J, Kefalides N, Macarak E. Susceptibility of endothelial
cells derived from different blood vessels to common viruses. In Vitro
Cell Dev Biol 1986;22:397–401.
99. Friedman H. Infection of endothelial cells by common human viruses. Rev
Infect Dis 1989;11(suppl):S700–4.
100. Friedman HM, Macarak EJ, MacGregor RR, Wolfe J, Kefalides NA. Virus
infection of endothelial cells. J Infect Dis 1981;143:266–73.
101. Ho DD, Rota TR, Andrews CA, Hirsch MS. Replication of human cyto-
megalovirus in endothelial cells. J Infect Dis 1984;150:956–7.
102. Hoxie JA, Matthews DM, Cines DB. Infection of human endothelial cells
by human T-cell leukemia virus type I. Proc Natl Acad Sci USA 1984;81:
7591–5.
103. Wiley CA, Schrier RD, Nelson JA, Lampert PW, Oldstone MBA. Cellular
localization of human immunodeficiency virus infection within the brains
of acquired immune deficiency syndrome patients. Proc Natl Acad Sci
USA 1986;83:7089–93.
104. Butthep P, Bunyaratvej A, Bhamarapravati N. Dengue virus and endothelial
cell: a related phenomenon to thrombocytopenia and granulocytopenia
in Dengue hemorrhagic fever. Southeast Asian J Trop Med Public Health
1993;24:246–9.
105. Bevilacqua M, Pober J, Wheeler M, Cotran R, Gimbrone M. Interleukin-1
activation of vascular endothelium: effects on procoagulant activity and
leucocyte adhesion. Am J Pathol 1985;121:394–403.
106. Adams DH, Wyner LR, Karnovsky MJ. Experimental graft arteriosclerosis.
2: Immunocytochemical analysis of lesion development. Transplantation
1993;56:794–9.
107. Schorer A, Kaplan M, Rao G, Moldow C. Interleukin-1 stimulates endo-
thelial cell tissue factor production and expression by a prostaglandin-
independent mechanism. Thromb Haemost 1986;56:256–9.
108. van Dam-Mieras MCE, Muller AD, van Hinsbergh VWM, Mullers WJHA,
Bomans PHH, Bruggeman CA. The procoagulant response of cyto-
megalovirus infected endothelial cells. Thromb Haemost 1992;68:
364–70.
109. van Dam-Mieras MCE, Bruggeman CA, Muller AD, Debie WHM, Zwaal
RFA. Induction of endothelial cell procoagulant activity by cytomega-
lovirus infection. Thromb Res 1987;47:69.
110. Etingin OR, Silverstein RL, Friedman HM, Hajjar DP. Viral activation of
the coagulation cascade: molecular interactions at the surface of infected
endothelial cells. Cell 1990;61:657–62.
111. Visser MR, Tracy PB, Vercelotti GM, Goodman JL, White JG, Jacob HS.
Enhanced thrombin generation and platelet binding on herpes simplex
virus–infected endothelium. Proc Natl Acad Sci USA 1988;85:8227–30.
112. Etingin OR, Silverstein RL, Hajjar DP. Identification of a monocyte receptor
on herpes virus–infected cells. Proc Natl Acad Sci USA 1991;88:7200–3.
113. Dudding L, Haskel S, Clark BD, Auron PE, Sporn S, Huang ES. Cyto-
megalovirus infection stimulates expression of monocyte associated me-
diator genes. J Immunol 1989;143:3343–52.
JID 1999;180 (July) Infectious Diseases and Coagulation Disorders 185
114. Smith PD, Saini SS, Raffeld M, Manischewitz JF, Wahl SM. Cytomega-
lovirus induction of tumor necrosis factor-a by human monocytes and
mucosal macrophages. J Clin Invest 1992;90:1642–8.
115. Almeida GD, Porada CD, St Jeor S, Ascensao J. Human cytomegalovirus
alters interleukin 6 production by endothelial cells. Blood 1994;83:370–6.
116. Pryzdial ELG, Wright JF. Prothrombinase assembly on an enveloped virus:
evidence that the cytomegalovirus surface contains procoagulant phos-
pholipid. Blood 1994;84:3749–57.
117. Aloia RC, Tian H, Jensen FC. Lipid composition and fluidity of the human
immunodeficiency virus envelope and host cell plasma membranes. Proc
Natl Acad Sci USA 1993;90:5181–5.
118. Voss R, Matthias FR, Borkowski G, Reitz D. Activation and inhibition of
fibrinolysis in septic patients in an intensive care unit. Br J Haematol
1990;75:99–102.
119. van der Poll T, Levi M, Buller HR, et al. Fibrinolytic response to tumor
necrosis factor in healthy subjects. J Exp Med 1991;174:729–73.
120. Biemond BJ, Levi M, ten Cate H, et al. Plasminogen activator and PAI-I
release during experimental endotoxemia in chimpanzees: effects of var-
ious interventions in the cytokine and coagulation cascades. Clin Sci
1995;88:587–94.
121. Esmon CT. The regulation of natural anticoagulant pathways. Science
1987;235:1348–52.
122. Sugerman RW, Church JA, Goldsmith JC, Ens GE. Acquired protein S
deficiency in children infected with human immunodeficiency virus. Pe-
diatr Infect Dis J 1996;15:106–11.
123. Stahl CP, Wideman CS, Spira TJ, Haff EC, Hixon GJ, Evatt BL. Protein
S deficiency in men with long term human immunodeficiency virus in-
fection. Blood 1993;81:1801–7.
124. Lafeuillade A, Alessi MC, Poizot-Martin I, et al. Endothelial cell dysfunc-
tion in HIV infection. J Acquir Immune Defic Syndr 1992;5:127–31.
125. Bissuel F, Verruyer M, Causse X, Dechavane M, Trepo C. Acquired protein
S deficiency: correlation with advanced disease in HIV-infected patients.
J Acquir Immune Defic Syndr 1992;5:484–9.
126. Malia RG, Kitchen S, Greaves M, Preston FE. Inhibition of activated
protein C and its cofactor protein S by antiphospholipid antibodies. Br
J Haematol 1990;76:101–7.
127. Lo SCL, Salem HH, Howard MA, Oldmeadow MJ, Firkin BG. Studies of
natural anticoagulant proteins and anticardiolipin antibodies in patients
with the lupus anticoagulant. Br J Haematol 1990;76:380–6.
128. Hassell KL, Kressin DC, Neumann A, Ellison R, Marlar RA. Correlation
of antiphospholipid antibodies and protein S deficiency with thrombosis
in HIV-infected men. Blood Coagul Fibrinolysis 1994;5:455–62.
129. Llorente MR, Carton JA, Carcaba V, et al. Antiphospholipid antibodies in
human immunodeficiency virus infection. Med Clin (Barc) 1994;103:
10–3.
130. Levin J. Bleeding with infectious diseases. In: Ratnoff OD, Forbes CD, eds.
Disorders of hemostasis. New York: Grune & Stratton, 1984:367–78.
131. Kelton J, Neame P. Hemorrhagic complications of infection. In: Hemostasis
and thrombosis. Philadelphia, JB Lippincott 1987:965–74.
132. Bierman HR, Nelson ER. Hematodepressive virus diseases of Thailand.
Ann Intern Med 1965;62:867–84.
133. Nakao S, Lai CJ, Young NS. Dengue virus, a flavivirus, propagates in
human bone marrow progenitors and hematopoietic cell lines. Blood
1989;74:1235–40.
134. Na-Nakorn S, Suingdumrong A, Pootrakul S, Bhamarapravati N. Bone
marrow studies in Thai hemorrhagic fever. Bull WHO 1966;35:54–5.
135. Halstead SB. Antibody, macrophages, Dengue virus infection, shock and
hemorrhage: a pathogenetic cascade. Rev Infect Dis 1989;11(suppl):
S830–9.
136. Terada H, Baldini M, Ebbe S, Madoff MA. Interaction of Influenza virus
with blood platelets. Blood 1966;28:213–28.
137. Stemerman MB. Vascular intimal components: precursors of thrombosis.
Prog Hemost Thromb 1974;2:1–47.
138. Curwen KD, Gimbrone MA Jr, Handin RI. In vitro studies of thrombores-
istance: the role of prostacyclin (PGI2) in platelet adhesion to cultured
normal and virally transformed human vascular endothelial cells. Lab
Invest 1980;42:366–74.
139. Kolars CP, Spink WW. Thrombopenic purpura as a complication of mumps.
JAMA 1958;168:2213–5.
140. Graham DY, Brown CH III, Benrey J, Butel JS. Thrombocytopenia: a
complication of mumps. JAMA 1974;227:1162–4.
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